Clinical trials help researchers answer important medical questions, providing information that may help with the development of future treatment options. Clinical trials are conducted to determine if investigational treatments (such as new drugs, procedures, or medical devices) are safe and effective, so that the regulatory authority can decide whether they can be approved for use as a treatment.
Participation in a clinical trial is voluntary. You can withdraw at any time, for any reason (or no reason at all), and doing so will not affect the care you may be receiving now and may receive in the future.
Disclaimer: the videos and the brochure were produced by Biogen, a pharmaceutical company with whom we collaborate. This material does not intend to favor one or the other clinical trial, and CurePSP remains fully impartial in its support of clinical research.
Current Clinical Trials
For a current list of available clinical trials (sourced from the National Institutes of Health website, clinicaltrials.gov), please click on the following links:
Clinical Research Studies
The AMULET study: A clinical research study for people living with MSA
Dear MSA patients and caregivers: Lundbeck is starting to recruit for a phase II clinical trial to evaluate the clinical safety, tolerability, and efficacy of a new treatment in MSA. To learn more about this study and dedicated effort, please click here.
Modus Outcome – Patients & Caregivers Interviews
A pharmaceutical company is working with Modus Outcomes and CurePSP with the goal to better understand PSP symptoms and how PSP impacts everyday life of patients and caregivers. To learn more about the study and to participate, please click here.
The Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) consortium is dedicated to conducting clinical research in PSP, CBD, and related diseases. There are currently 14 clinical study sites in the United States and Canada. To learn more about this study, please click here.
The 4 Repeat Tauopathy Neuroimaging Initiative. The goal of this study is to identify the most reliable methods of analysis for tracking CBD and PSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) ‟biomarkers.” To learn more about this study, please click here.
The FTD Disorders Registry
The Registry is an online database to collect information from those affected by all types of prime of life brain diseases, such as PSP, CBD, and related. Persons diagnosed, (current/former) caregivers, family, and friends can join. As a member of the Registry, you can help us advance the science and move faster toward finding treatments and cures. Join the registry here.